Cancer
We’re investigating the biological basis of many solid and blood borne malignancies, advancing diagnosis, developing and trialing new therapies, and improving all aspects of the management of cancer including palliative care.
Program Leaders
Our Cancer Program Leaders are supported by six Cancer Program Group Leaders and a team of more than 60 group members. View a full listing of Cancer Program researchers.
Program Groups
Clinical Trials
Clinical trials are an essential component of modern healthcare and provide evidence to evaluate the safety and efficacy of new treatments, diagnostics and health interventions and offer alternative options for patients with unmet needs under current standards of care. Explore Cancer Program clinical trials currently running at Mater Research below or learn more about Mater Clinical Trials.
-
ADELE
-
AMT-151-01
-
ANZadapt
-
B-Cell Malignancies new treatment
-
CAMBRIA-2: Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next-Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine T
-
CAPItello-281
-
DEPART - Seeking cancer patients with nerve pain
-
Do you have newly diagnosed prostate cancer?
-
DYNASTY-Breast02
-
ELAINE-3
-
FOCUSau: Improving the wellbeing of people with advanced cancer and their family carers
-
Follicular Lymphoma
-
frontMIND - A new treatment for newly diagnosed lymphoma
-
HyNOVA - Hyperthermic and Normothermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III epithelial OVArian, fallopian tube and primary peritoneal cancer
-
INX-315-01
-
IOS-1002-201 - administered alone and in combination with a PD-1 monoclonal antibody in advanced solid tumors
-
Keynote-B15
-
lidERA - Trialing a new oral hormone receptor blocker in estrogen receptor positive breast cancer
-
MedCan 3 - Medicinal cannabis to relieve symptoms of advanced cancer in palliative care patients
-
Medical Oncology Trials
-
Medicinal cannabis for palliative care patients - exploring detection of cannabis in saliva, urine and blood tests.
-
PARAGON-II
-
RC-48
-
VIKTORIA-1
-
XL092-304
-
Zn-c3 - A potential new treatment for advanced ovarian, peritoneal or fallopian tube cancer
-
ZN-c3-002
Latest news
-
News
PhD student secures fellowship to pioneer mRNA vaccine for rare blood disorder
-
News
Clinical trials give hope to current and future breast cancer patients
-
News
Outstanding achievements recognised at annual Mater People Awards
-
News
Celebrating the Future Leaders of Mater Research at 2024 Symposium